The meta-analysis from 2019 by Dicembrini et al. is the biggest to date about SGLT2 inhibitors and the incidence of cancer includes 48,185 patients, among them 27,744 patients in the SGLT2 group. This evidence concerns the gene SLC5A2 and cancer.